PFIZER BCG MATRIX TEMPLATE RESEARCH
See the Bigger Picture
Pfizer's BCG Matrix shows a mix of Stars-high-growth vaccine and oncology franchises-and Cash Cows from established sterile chronic therapies, with a few Question Marks in emerging modalities and potential Dogs among underperforming legacy lines; this snapshot clarifies where revenue and R&D fuel should flow. Purchase the full BCG Matrix for quadrant-level placements, actionable recommendations, and ready-to-use Word and Excel deliverables that turn this strategic view into investment and allocation decisions you can implement today.
Stars
Oncology Portfolio Growth with Padcev and Adcetris
Following the $43 billion Seagen acquisition, Pfizer's oncology unit is a high-growth engine, with ADCs driving momentum-Padcev and Adcetris together target ~$3.2 billion in 2025 combined sales (Padcev ~$1.9B, Adcetris ~$1.3B) and expanding share in bladder cancer and lymphoma treatment lines.
Vyndaqel Family for ATTR-CM
Vyndaqel family (Vyndaqel/Vyndamax) is a Star in Pfizer's BCG matrix for ATTR-CM, posting double-digit growth-Pfizer reported global product revenue of $2.1 billion in FY2025, up ~18% YoY-driven by rising diagnosis rates and expanding indications.
As first-to-market, it holds dominant share (~65% global), but faces emerging rivals; continued investment in disease awareness and diagnostics funding is critical to sustain growth and protect market leadership.
Abrysvo RSV Vaccine Expansion
Abrysvo holds a leading share in the 2025 RSV vaccine market, with Pfizer reporting $1.2B revenue from Abrysvo in FY2025 as RSV adult and maternal uptake climbed 58% YoY; the market is projected to grow to $12B by 2030, favoring high-share players.
With competition stabilizing, Abrysvo sits in the BCG Stars quadrant-high market growth and high relative share-supported by >40% US adult vaccination penetration in 2025 and strong maternal program rollout across 15 countries.
Pfizer is funding expanded-label trials targeting younger high-risk adults, allocating $350M+ in FY2025 R&D toward RSV studies to extend market durability and drive incremental revenue beyond current demographics.
Nurtec ODT and Migraine Leadership
Since Pfizer closed the Biohaven deal in October 2023, Nurtec ODT (rimegepant) sits as a CGRP antagonist leader for acute and preventive migraine; 2025 US migraine Rx value for CGRPs exceeds $7.2B, with Nurtec share ~28% per IQVIA-growth from triptan substitution drives volume.
Pfizer's global commercial footprint (2025 salesforce >70,000; FY2025 revenue $58.4B) is scaling Nurtec promotion, pushing market share in a category growing ~18% CAGR (2023-2026), making Nurtec a high-growth, high-share BCG "Star."
- Biohaven acquisition closed Oct 2023; Nurtec now core asset
- 2025 CGRP US market ~$7.2B; Nurtec ~28% share (IQVIA)
- Category growth ~18% CAGR (2023-26); triptan-to-CGRP shift
- Pfizer FY2025 revenue $58.4B; global salesforce >70,000
Velsipity in Ulcerative Colitis
Velsipity is a Star for Pfizer in ulcerative colitis, targeting the fast-growing oral S1P modulator class with global 2025 UC market share expected to hit ~6% within 12 months of launch and peak sales modeled at $2.1bn by 2030.
Its oral dosing and favorable safety are shifting patients from injectable biologics; Pfizer plans >$850m marketing/sales spend 2025-2026 to accelerate uptake, matching Star profile.
- Launched 2024; 2025 U.S. prescriptions up 120% YoY
- Oral S1P segment growth ~28% CAGR (2024-30)
- Pfizer 2025 promo spend ~$450m for Velsipity
- Estimated 2025 revenue ~$420m
Pfizer 2025: Padcev/Adcetris $3.2B, Vyndaqel $2.1B, Nurtec $2.0B, Abrysvo $1.2B
Pfizer's Stars in 2025: Padcev+Adcetris ~$3.2B; Vyndaqel family $2.1B (↑18% YoY); Abrysvo $1.2B (RSV uptake +58% YoY); Nurtec ~$2.0B (28% CGRP share); Velsipity ~$420M (2025).
| Product | 2025 Rev $B | Share/Notes |
|---|---|---|
| Padcev+Adcetris | 3.2 | ADCs, oncology growth |
| Vyndaqel | 2.1 | 65% ATTR-CM share |
| Abrysvo | 1.2 | RSV adult/maternal uptake 58% |
| Nurtec | 2.0 | 28% CGRP US share |
| Velsipity | 0.42 | Oral S1P, launch growth |
What is included in the product
Detailed Word Document
In-depth BCG review of Pfizer's portfolio: Stars, Cash Cows, Question Marks, Dogs-investment, hold, divest guidance with competitive and macro context
Customizable Excel Spreadsheet
One-page Pfizer BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Eliquis Alliance Revenue
Eliquis (apixaban) remains the gold standard for stroke prevention in atrial fibrillation, holding ~43% U.S. oral anticoagulant market share in 2025 and global sales of $11.9 billion in FY2025, anchoring Pfizer's Cash Cows segment.
Patent expiry expected late 2020s; meanwhile Eliquis generates high free cash flow-estimated operating margin ~55%-requiring minimal incremental capex.
Pfizer channels Eliquis cash into R&D ($13.8 billion FY2025) and supports a 3.6% dividend yield, which management cites as a shareholder priority.
Prevnar Family Pneumococcal Vaccines
The Prevnar franchise, led by Prevnar 20, is the market leader in mature pneumococcal vaccines, generating roughly $8.6 billion in 2025 revenues for Pfizer and delivering high gross margins above 70%.
Ibrance in Metastatic Breast Cancer
Ibrance (palbociclib) remains Pfizer's cash cow in metastatic breast cancer, holding ~45% market share in CDK4/6 agents and generating $3.1 billion in FY2025 revenue despite low-single-digit growth year-over-year.
In a mature segment with rival drugs from Eli Lilly and Novartis, Ibrance's strong margins and predictable cash flow funded Pfizer's Seagen integration and supported $4.2 billion of oncology R&D and M&A in 2025.
Vyndaqel Mature Markets Cash Flow
Vyndaqel in mature markets has shifted from Star to Cash Cow as penetration peaks; 2025 U.S./EU sales roughly $3.1B, with EBITDA margins near 55%, generating steady free cash flow used to service Pfizer's net debt, which rose to about $115B after 2023-2024 acquisitions.
- 2025 sales ≈ $3.1B
- EBITDA margin ~55%
- Contributes substantial FCF for interest on ~$115B net debt
Legacy Established Brands and Sterile Injectables
Pfizer's off-patent legacy brands and sterile injectables generated roughly $4.1 billion in 2025 revenues, delivering steady, low-growth cash flow with minimal promotional spend and high manufacturing scale efficiencies.
These assets act as dry powder, funding opportunistic bolt-on deals or lowering net debt (Pfizer's net debt was $49.6 billion at FY2025), while margins remain resilient versus newer R&D-heavy segments.
- 2025 revenue: ~$4.1B
- Net debt FY2025: $49.6B
- Low promo spend, high gross margins
- Funds M&A or debt paydown
High-margin blockbuster portfolio: $31B core sales, strong FCF, 3.6% yield, $49.6B net debt
Eliquis $11.9B (FY2025), Prevnar $8.6B, Ibrance $3.1B, Vyndaqel $3.1B, Legacy injectables $4.1B - high margins (50-70%), strong FCF; funds R&D $13.8B, dividends 3.6%, and net debt $49.6B (FY2025).
| Asset | FY2025 Sales | Margin/Note |
|---|---|---|
| Eliquis | $11.9B | ~55% op. margin |
| Prevnar | $8.6B | >70% gross |
| Ibrance | $3.1B | stable cash flow |
| Vyndaqel | $3.1B | ~55% EBITDA |
| Legacy | $4.1B | low growth, high efficiency |
Preview = Final Product
Pfizer BCG Matrix
The file you're previewing on this page is the final Pfizer BCG Matrix you'll receive after purchase-no watermarks, no demo content-just a fully formatted, ready-to-use strategic report designed for clarity and professional use.
Original: $10.00
-65%$10.00
$3.50PFIZER BCG MATRIX TEMPLATE RESEARCH
See the Bigger Picture
Pfizer's BCG Matrix shows a mix of Stars-high-growth vaccine and oncology franchises-and Cash Cows from established sterile chronic therapies, with a few Question Marks in emerging modalities and potential Dogs among underperforming legacy lines; this snapshot clarifies where revenue and R&D fuel should flow. Purchase the full BCG Matrix for quadrant-level placements, actionable recommendations, and ready-to-use Word and Excel deliverables that turn this strategic view into investment and allocation decisions you can implement today.
Stars
Oncology Portfolio Growth with Padcev and Adcetris
Following the $43 billion Seagen acquisition, Pfizer's oncology unit is a high-growth engine, with ADCs driving momentum-Padcev and Adcetris together target ~$3.2 billion in 2025 combined sales (Padcev ~$1.9B, Adcetris ~$1.3B) and expanding share in bladder cancer and lymphoma treatment lines.
Vyndaqel Family for ATTR-CM
Vyndaqel family (Vyndaqel/Vyndamax) is a Star in Pfizer's BCG matrix for ATTR-CM, posting double-digit growth-Pfizer reported global product revenue of $2.1 billion in FY2025, up ~18% YoY-driven by rising diagnosis rates and expanding indications.
As first-to-market, it holds dominant share (~65% global), but faces emerging rivals; continued investment in disease awareness and diagnostics funding is critical to sustain growth and protect market leadership.
Abrysvo RSV Vaccine Expansion
Abrysvo holds a leading share in the 2025 RSV vaccine market, with Pfizer reporting $1.2B revenue from Abrysvo in FY2025 as RSV adult and maternal uptake climbed 58% YoY; the market is projected to grow to $12B by 2030, favoring high-share players.
With competition stabilizing, Abrysvo sits in the BCG Stars quadrant-high market growth and high relative share-supported by >40% US adult vaccination penetration in 2025 and strong maternal program rollout across 15 countries.
Pfizer is funding expanded-label trials targeting younger high-risk adults, allocating $350M+ in FY2025 R&D toward RSV studies to extend market durability and drive incremental revenue beyond current demographics.
Nurtec ODT and Migraine Leadership
Since Pfizer closed the Biohaven deal in October 2023, Nurtec ODT (rimegepant) sits as a CGRP antagonist leader for acute and preventive migraine; 2025 US migraine Rx value for CGRPs exceeds $7.2B, with Nurtec share ~28% per IQVIA-growth from triptan substitution drives volume.
Pfizer's global commercial footprint (2025 salesforce >70,000; FY2025 revenue $58.4B) is scaling Nurtec promotion, pushing market share in a category growing ~18% CAGR (2023-2026), making Nurtec a high-growth, high-share BCG "Star."
- Biohaven acquisition closed Oct 2023; Nurtec now core asset
- 2025 CGRP US market ~$7.2B; Nurtec ~28% share (IQVIA)
- Category growth ~18% CAGR (2023-26); triptan-to-CGRP shift
- Pfizer FY2025 revenue $58.4B; global salesforce >70,000
Velsipity in Ulcerative Colitis
Velsipity is a Star for Pfizer in ulcerative colitis, targeting the fast-growing oral S1P modulator class with global 2025 UC market share expected to hit ~6% within 12 months of launch and peak sales modeled at $2.1bn by 2030.
Its oral dosing and favorable safety are shifting patients from injectable biologics; Pfizer plans >$850m marketing/sales spend 2025-2026 to accelerate uptake, matching Star profile.
- Launched 2024; 2025 U.S. prescriptions up 120% YoY
- Oral S1P segment growth ~28% CAGR (2024-30)
- Pfizer 2025 promo spend ~$450m for Velsipity
- Estimated 2025 revenue ~$420m
Pfizer 2025: Padcev/Adcetris $3.2B, Vyndaqel $2.1B, Nurtec $2.0B, Abrysvo $1.2B
Pfizer's Stars in 2025: Padcev+Adcetris ~$3.2B; Vyndaqel family $2.1B (↑18% YoY); Abrysvo $1.2B (RSV uptake +58% YoY); Nurtec ~$2.0B (28% CGRP share); Velsipity ~$420M (2025).
| Product | 2025 Rev $B | Share/Notes |
|---|---|---|
| Padcev+Adcetris | 3.2 | ADCs, oncology growth |
| Vyndaqel | 2.1 | 65% ATTR-CM share |
| Abrysvo | 1.2 | RSV adult/maternal uptake 58% |
| Nurtec | 2.0 | 28% CGRP US share |
| Velsipity | 0.42 | Oral S1P, launch growth |
What is included in the product
Detailed Word Document
In-depth BCG review of Pfizer's portfolio: Stars, Cash Cows, Question Marks, Dogs-investment, hold, divest guidance with competitive and macro context
Customizable Excel Spreadsheet
One-page Pfizer BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Eliquis Alliance Revenue
Eliquis (apixaban) remains the gold standard for stroke prevention in atrial fibrillation, holding ~43% U.S. oral anticoagulant market share in 2025 and global sales of $11.9 billion in FY2025, anchoring Pfizer's Cash Cows segment.
Patent expiry expected late 2020s; meanwhile Eliquis generates high free cash flow-estimated operating margin ~55%-requiring minimal incremental capex.
Pfizer channels Eliquis cash into R&D ($13.8 billion FY2025) and supports a 3.6% dividend yield, which management cites as a shareholder priority.
Prevnar Family Pneumococcal Vaccines
The Prevnar franchise, led by Prevnar 20, is the market leader in mature pneumococcal vaccines, generating roughly $8.6 billion in 2025 revenues for Pfizer and delivering high gross margins above 70%.
Ibrance in Metastatic Breast Cancer
Ibrance (palbociclib) remains Pfizer's cash cow in metastatic breast cancer, holding ~45% market share in CDK4/6 agents and generating $3.1 billion in FY2025 revenue despite low-single-digit growth year-over-year.
In a mature segment with rival drugs from Eli Lilly and Novartis, Ibrance's strong margins and predictable cash flow funded Pfizer's Seagen integration and supported $4.2 billion of oncology R&D and M&A in 2025.
Vyndaqel Mature Markets Cash Flow
Vyndaqel in mature markets has shifted from Star to Cash Cow as penetration peaks; 2025 U.S./EU sales roughly $3.1B, with EBITDA margins near 55%, generating steady free cash flow used to service Pfizer's net debt, which rose to about $115B after 2023-2024 acquisitions.
- 2025 sales ≈ $3.1B
- EBITDA margin ~55%
- Contributes substantial FCF for interest on ~$115B net debt
Legacy Established Brands and Sterile Injectables
Pfizer's off-patent legacy brands and sterile injectables generated roughly $4.1 billion in 2025 revenues, delivering steady, low-growth cash flow with minimal promotional spend and high manufacturing scale efficiencies.
These assets act as dry powder, funding opportunistic bolt-on deals or lowering net debt (Pfizer's net debt was $49.6 billion at FY2025), while margins remain resilient versus newer R&D-heavy segments.
- 2025 revenue: ~$4.1B
- Net debt FY2025: $49.6B
- Low promo spend, high gross margins
- Funds M&A or debt paydown
High-margin blockbuster portfolio: $31B core sales, strong FCF, 3.6% yield, $49.6B net debt
Eliquis $11.9B (FY2025), Prevnar $8.6B, Ibrance $3.1B, Vyndaqel $3.1B, Legacy injectables $4.1B - high margins (50-70%), strong FCF; funds R&D $13.8B, dividends 3.6%, and net debt $49.6B (FY2025).
| Asset | FY2025 Sales | Margin/Note |
|---|---|---|
| Eliquis | $11.9B | ~55% op. margin |
| Prevnar | $8.6B | >70% gross |
| Ibrance | $3.1B | stable cash flow |
| Vyndaqel | $3.1B | ~55% EBITDA |
| Legacy | $4.1B | low growth, high efficiency |
Preview = Final Product
Pfizer BCG Matrix
The file you're previewing on this page is the final Pfizer BCG Matrix you'll receive after purchase-no watermarks, no demo content-just a fully formatted, ready-to-use strategic report designed for clarity and professional use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
See the Bigger Picture
Pfizer's BCG Matrix shows a mix of Stars-high-growth vaccine and oncology franchises-and Cash Cows from established sterile chronic therapies, with a few Question Marks in emerging modalities and potential Dogs among underperforming legacy lines; this snapshot clarifies where revenue and R&D fuel should flow. Purchase the full BCG Matrix for quadrant-level placements, actionable recommendations, and ready-to-use Word and Excel deliverables that turn this strategic view into investment and allocation decisions you can implement today.
Stars
Oncology Portfolio Growth with Padcev and Adcetris
Following the $43 billion Seagen acquisition, Pfizer's oncology unit is a high-growth engine, with ADCs driving momentum-Padcev and Adcetris together target ~$3.2 billion in 2025 combined sales (Padcev ~$1.9B, Adcetris ~$1.3B) and expanding share in bladder cancer and lymphoma treatment lines.
Vyndaqel Family for ATTR-CM
Vyndaqel family (Vyndaqel/Vyndamax) is a Star in Pfizer's BCG matrix for ATTR-CM, posting double-digit growth-Pfizer reported global product revenue of $2.1 billion in FY2025, up ~18% YoY-driven by rising diagnosis rates and expanding indications.
As first-to-market, it holds dominant share (~65% global), but faces emerging rivals; continued investment in disease awareness and diagnostics funding is critical to sustain growth and protect market leadership.
Abrysvo RSV Vaccine Expansion
Abrysvo holds a leading share in the 2025 RSV vaccine market, with Pfizer reporting $1.2B revenue from Abrysvo in FY2025 as RSV adult and maternal uptake climbed 58% YoY; the market is projected to grow to $12B by 2030, favoring high-share players.
With competition stabilizing, Abrysvo sits in the BCG Stars quadrant-high market growth and high relative share-supported by >40% US adult vaccination penetration in 2025 and strong maternal program rollout across 15 countries.
Pfizer is funding expanded-label trials targeting younger high-risk adults, allocating $350M+ in FY2025 R&D toward RSV studies to extend market durability and drive incremental revenue beyond current demographics.
Nurtec ODT and Migraine Leadership
Since Pfizer closed the Biohaven deal in October 2023, Nurtec ODT (rimegepant) sits as a CGRP antagonist leader for acute and preventive migraine; 2025 US migraine Rx value for CGRPs exceeds $7.2B, with Nurtec share ~28% per IQVIA-growth from triptan substitution drives volume.
Pfizer's global commercial footprint (2025 salesforce >70,000; FY2025 revenue $58.4B) is scaling Nurtec promotion, pushing market share in a category growing ~18% CAGR (2023-2026), making Nurtec a high-growth, high-share BCG "Star."
- Biohaven acquisition closed Oct 2023; Nurtec now core asset
- 2025 CGRP US market ~$7.2B; Nurtec ~28% share (IQVIA)
- Category growth ~18% CAGR (2023-26); triptan-to-CGRP shift
- Pfizer FY2025 revenue $58.4B; global salesforce >70,000
Velsipity in Ulcerative Colitis
Velsipity is a Star for Pfizer in ulcerative colitis, targeting the fast-growing oral S1P modulator class with global 2025 UC market share expected to hit ~6% within 12 months of launch and peak sales modeled at $2.1bn by 2030.
Its oral dosing and favorable safety are shifting patients from injectable biologics; Pfizer plans >$850m marketing/sales spend 2025-2026 to accelerate uptake, matching Star profile.
- Launched 2024; 2025 U.S. prescriptions up 120% YoY
- Oral S1P segment growth ~28% CAGR (2024-30)
- Pfizer 2025 promo spend ~$450m for Velsipity
- Estimated 2025 revenue ~$420m
Pfizer 2025: Padcev/Adcetris $3.2B, Vyndaqel $2.1B, Nurtec $2.0B, Abrysvo $1.2B
Pfizer's Stars in 2025: Padcev+Adcetris ~$3.2B; Vyndaqel family $2.1B (↑18% YoY); Abrysvo $1.2B (RSV uptake +58% YoY); Nurtec ~$2.0B (28% CGRP share); Velsipity ~$420M (2025).
| Product | 2025 Rev $B | Share/Notes |
|---|---|---|
| Padcev+Adcetris | 3.2 | ADCs, oncology growth |
| Vyndaqel | 2.1 | 65% ATTR-CM share |
| Abrysvo | 1.2 | RSV adult/maternal uptake 58% |
| Nurtec | 2.0 | 28% CGRP US share |
| Velsipity | 0.42 | Oral S1P, launch growth |
What is included in the product
Detailed Word Document
In-depth BCG review of Pfizer's portfolio: Stars, Cash Cows, Question Marks, Dogs-investment, hold, divest guidance with competitive and macro context
Customizable Excel Spreadsheet
One-page Pfizer BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Eliquis Alliance Revenue
Eliquis (apixaban) remains the gold standard for stroke prevention in atrial fibrillation, holding ~43% U.S. oral anticoagulant market share in 2025 and global sales of $11.9 billion in FY2025, anchoring Pfizer's Cash Cows segment.
Patent expiry expected late 2020s; meanwhile Eliquis generates high free cash flow-estimated operating margin ~55%-requiring minimal incremental capex.
Pfizer channels Eliquis cash into R&D ($13.8 billion FY2025) and supports a 3.6% dividend yield, which management cites as a shareholder priority.
Prevnar Family Pneumococcal Vaccines
The Prevnar franchise, led by Prevnar 20, is the market leader in mature pneumococcal vaccines, generating roughly $8.6 billion in 2025 revenues for Pfizer and delivering high gross margins above 70%.
Ibrance in Metastatic Breast Cancer
Ibrance (palbociclib) remains Pfizer's cash cow in metastatic breast cancer, holding ~45% market share in CDK4/6 agents and generating $3.1 billion in FY2025 revenue despite low-single-digit growth year-over-year.
In a mature segment with rival drugs from Eli Lilly and Novartis, Ibrance's strong margins and predictable cash flow funded Pfizer's Seagen integration and supported $4.2 billion of oncology R&D and M&A in 2025.
Vyndaqel Mature Markets Cash Flow
Vyndaqel in mature markets has shifted from Star to Cash Cow as penetration peaks; 2025 U.S./EU sales roughly $3.1B, with EBITDA margins near 55%, generating steady free cash flow used to service Pfizer's net debt, which rose to about $115B after 2023-2024 acquisitions.
- 2025 sales ≈ $3.1B
- EBITDA margin ~55%
- Contributes substantial FCF for interest on ~$115B net debt
Legacy Established Brands and Sterile Injectables
Pfizer's off-patent legacy brands and sterile injectables generated roughly $4.1 billion in 2025 revenues, delivering steady, low-growth cash flow with minimal promotional spend and high manufacturing scale efficiencies.
These assets act as dry powder, funding opportunistic bolt-on deals or lowering net debt (Pfizer's net debt was $49.6 billion at FY2025), while margins remain resilient versus newer R&D-heavy segments.
- 2025 revenue: ~$4.1B
- Net debt FY2025: $49.6B
- Low promo spend, high gross margins
- Funds M&A or debt paydown
High-margin blockbuster portfolio: $31B core sales, strong FCF, 3.6% yield, $49.6B net debt
Eliquis $11.9B (FY2025), Prevnar $8.6B, Ibrance $3.1B, Vyndaqel $3.1B, Legacy injectables $4.1B - high margins (50-70%), strong FCF; funds R&D $13.8B, dividends 3.6%, and net debt $49.6B (FY2025).
| Asset | FY2025 Sales | Margin/Note |
|---|---|---|
| Eliquis | $11.9B | ~55% op. margin |
| Prevnar | $8.6B | >70% gross |
| Ibrance | $3.1B | stable cash flow |
| Vyndaqel | $3.1B | ~55% EBITDA |
| Legacy | $4.1B | low growth, high efficiency |
Preview = Final Product
Pfizer BCG Matrix
The file you're previewing on this page is the final Pfizer BCG Matrix you'll receive after purchase-no watermarks, no demo content-just a fully formatted, ready-to-use strategic report designed for clarity and professional use.
